Healthcare
Colfax Corp(CFX)
Live Price
Offline$22.68
-1.56% today
1Y Change
-31.62%
Window
Jun 25, 2025 → Jun 18, 2026
- Market Cap
- $1.38B
- Revenue Growth
- +6.7%
- EPS Growth
- -38.3%
- Dividend Yield
- 0.0%
Coverage: 244 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Colfax Corp (CFX) is a Healthcare stock with a market cap of $1.38B and listed on NYSE. The stock last traded around $22.68 and down 31.6% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +6.7%, EPS growth of -38.3%, a dividend yield of 0.0%. What stands out right now is revenue +6.7%, EPS -38.3%, free cash flow +129.6% with operating margin -52.6% and ROIC -35.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CFX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.7% vs +7.6% peer median
Operating Margin
Below sector median
-52.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2022 was reported on Apr 27, 2022 with an EPS surprise of -31.6% and a revenue surprise of +0.8%.
The operating picture looks softer than before
Revenue is at +6.7% and EPS is at -38.3%, with operating margin around -52.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Δ | 1D | 5D | 20D |
|---|---|---|---|---|
2022 Apr 27, 2022 | -31.6% | +0.4% | +4.1% | -15.5% |
2022 Feb 22, 2022 | +2.9% | +0.4% | +4.1% | -15.5% |
2021 Nov 4, 2021 | +1.3% | +0.4% | +4.1% | -15.5% |
Benchmark Edge
CFX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CFX
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CFX Max Drawdown
-41.99%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CFX and SPY.
Company Overview
Colfax Corp
NYSE
Enovis Corporation is a medical technology company focused on developing and manufacturing innovative orthopedic care and rehabilitation solutions. The company operates primarily through two business segments: Prevention & Recovery, which encompasses bracing, supports, and other therapies designed to prevent injury and enhance patient recovery, and Reconstructive, which provides products for joint replacement and surgical interventions aimed at restoring patient mobility. Enovis has evolved from its origins as Colfax Corporation, previously a diversified industrial manufacturing firm, to a dedicated medtech enterprise following significant acquisitions and strategic divestitures, most notably the purchase of DJO for orthopedic platforms and the spinoff of its fabrication technology segment as ESAB Corporation. Leveraging a heritage of operational excellence and continuous improvement—principles rooted in the company’s founding by the Rales brothers—Enovis is committed to driving better clinical outcomes and transforming workflows in healthcare settings. It serves hospitals, clinics, and healthcare providers worldwide, contributing to advancements in patient care through innovations that improve mobility and quality of life. Today, Enovis is recognized for its strong focus on growth, industry leadership in orthopedics, and its vital role in the broader health technology sector.
- Leadership
- Mr. Damien McDonald
- Employees
- 7.4k
- Street Address
- 2711 Centerville Road, Suite 400
- Mailing
- Wilmington, DE, 19808
- Region
- Wilmington, DE, United States
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 0.6
- Price/Book
- 0.9
Growth
- Revenue
- +6.7%
- EPS
- -38.3%
- Free Cash Flow
- +129.6%
Profitability
- Gross Margin
- 59.8%
- Operating Margin
- -52.6%
- Net Margin
- -52.7%
- ROE
- -54.4%
- ROIC
- -35.9%
Balance Sheet
- Debt/Equity
- 0.93
- Current Ratio
- 2.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.